Supernus Pharmaceuticals
(NASDAQ:SUPN)
$34.11
0.37[1.10%]
At close: Mar 28
$34.11
0[0.00%]
After Hours: 4:05PM EDT
Consensus Rating1
Overweight
Highest Price Target1
$41.00
Lowest Price Target1
$40.00
Consensus Price Target1
$40.50

Supernus Pharmaceuticals Stock (NASDAQ:SUPN), Analyst Ratings, Price Targets, Predictions

Supernus Pharmaceuticals Inc has a consensus price target of $40.5, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Piper Sandler, and Piper Sandler on February 28, 2024, November 9, 2023, and October 25, 2023. With an average price target of $42 between Piper Sandler, Piper Sandler, and Piper Sandler, there's an implied 23.13% upside for Supernus Pharmaceuticals Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
1
Nov 23
1
Feb
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Supernus Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/28/2024SUPNBuy Now
Supernus Pharmaceuticals
$34.1120.2%Piper Sandler
David Amsellem
$45 → $41MaintainsOverweightGet Alert
11/09/2023SUPNBuy Now
Supernus Pharmaceuticals
$34.1126.06%Piper Sandler
David Amsellem
$42 → $43MaintainsOverweightGet Alert
10/25/2023SUPNBuy Now
Supernus Pharmaceuticals
$34.1123.13%Piper Sandler
David Amsellem
$43 → $42MaintainsOverweightGet Alert
05/10/2023SUPNBuy Now
Supernus Pharmaceuticals
$34.1134.86%Piper Sandler
David Amsellem
$45 → $46MaintainsOverweightGet Alert
01/23/2023SUPNBuy Now
Supernus Pharmaceuticals
$34.1137.79%Piper Sandler
David Amsellem
$40 → $47MaintainsOverweightGet Alert
08/31/2022SUPNBuy Now
Supernus Pharmaceuticals
$34.1111.4%Piper Sandler
David Amsellem
$33 → $38MaintainsOverweightGet Alert
04/13/2021SUPNBuy Now
Supernus Pharmaceuticals
$34.1117.27%Jefferies
David Steinberg
UpgradeHold → BuyGet Alert

FAQ

Q

What is the target price for Supernus Pharmaceuticals (SUPN)?

A

The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on February 28, 2024. The analyst firm set a price target for $41.00 expecting SUPN to rise to within 12 months (a possible 20.20% upside). 4 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?

A

The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.

Q

When was the last upgrade for Supernus Pharmaceuticals (SUPN)?

A

The last upgrade for Supernus Pharmaceuticals Inc happened on April 13, 2021 when Jefferies raised their price target to $40. Jefferies previously had a hold for Supernus Pharmaceuticals Inc.

Q

When was the last downgrade for Supernus Pharmaceuticals (SUPN)?

A

There is no last downgrade for Supernus Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on February 28, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.

Q

Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?

A

While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $45.00 to $41.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $34.11, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch